ABSTRACT
OBJECTIVE: The objective of this single-center observational study was to determine the clinical and hematologic responses to intravenous ferric carboxymaltose (FCM) in a cohort of pediatric patients with poor response to oral iron therapy. The occurrence of adverse events was systematically recorded for up to 96 hours after infusion. STUDY DESIGN: A retrospective cohort of 144 consecutive patients aged 18 months to < 18 years with iron deficiency anemia (IDA) or iron deficiency (ID) without anemia was investigated. All patients had failed oral iron therapy. The assessments before and after FCM treatment followed a predefined protocol. RESULTS: One hundred of 117 (85 %) of patients with complete data achieved the target ferritin level ≥ 30 µg/L after a single FCM dose. Of 77 patients with IDA and complete data, 38 (49%) showed a complete hematological response within 6-12 weeks; a complete or partial response was achieved by 83%. Clinical symptoms improved in 85% of all patients. In 92% of patients (n = 133 /144), FCM infusion was uneventful. During the 96-hour follow-up, five patients reported potentially related symptoms. No serious adverse events occurred. CONCLUSION: The study confirms the safety and efficacy of FCM in children (aged 18 months and older) and adolescents unresponsive to oral therapy, in real-world experience. Single-dose FCM treatment was followed by clinical improvement with advantages of safety, compliance, and lower cost compared with previous generation parenteral iron preparations that had to be administered in fractionated sessions.
Subject(s)
Anemia, Iron-Deficiency/drug therapy , Ferric Compounds/administration & dosage , Iron Metabolism Disorders/drug therapy , Maltose/analogs & derivatives , Administration, Intravenous , Adolescent , Anemia, Iron-Deficiency/pathology , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Iron Metabolism Disorders/pathology , Male , Maltose/administration & dosage , Prognosis , Retrospective StudiesSubject(s)
Aluminum Hydroxide/therapeutic use , Antacids/therapeutic use , Antipsychotic Agents/adverse effects , Clozapine/adverse effects , Metabolic Diseases/drug therapy , Adult , Antipsychotic Agents/blood , Clozapine/blood , Humans , Male , Metabolic Diseases/chemically induced , Psychotic Disorders/blood , Psychotic Disorders/drug therapyABSTRACT
Prolonged static sitting can lead to discomfort, pain, pressure sores, spinal curvatures, and loss of functional independence. In order to counteract these harmful effects, adjustable tilt and/or recline systems are often prescribed. Considering the current context of assistive technology service delivery and budget cuts, it is essential to have a better knowledge of the use of these technical aids and user's satisfaction with them. The purpose of this study was to characterize the use of powered tilt and recline systems. A questionnaire was developed for this purpose, and 40 subjects were interviewed at home. They were asked to identify, from a list of 25 objectives, the reasons for which they used their repositioning system and to rank these reasons in order of importance. For each objective, they were also asked to identify the frequency and range of use as well as their satisfaction level with their system. Results revealed that 97.5% of the subjects were using their powered tilt and recline system everyday, and their satisfaction was high. The main objectives for using this type of assistive technology were to increase comfort and to promote rest. Although mainly descriptive, results are of clinical relevance and can be helpful when selecting wheelchairs.
